Five-year costs per patient according to prophylactic regimen
. | Netherlands Intermediate-dose . | Sweden High-dose . | P . | Netherlands Intermediate-dose . | Sweden High-dose . | P . |
---|---|---|---|---|---|---|
Mean (SD), US$1000 . | Median (IQR), US$1000 . | |||||
Direct costs | ||||||
Factor use | 867 (380) | 1452 (483) | <.01 | 851 (647-1046) | 1474 (1154-1776) | <.01 |
Other health care | 5 (9) | 4 (6) | .28 | 2 (2-3) | 1 (1–3) | <.01 |
Indirect costs | ||||||
Lost production | 14 (50) | 1 (3) | .08 | 0 (0-0)* | 0 (0-0)* | .82 |
Total costs | 886 (382) | 1457 (484) | <.01 | 852 (659-1094) | 1475 (1155-1787) | <.01 |
. | Netherlands Intermediate-dose . | Sweden High-dose . | P . | Netherlands Intermediate-dose . | Sweden High-dose . | P . |
---|---|---|---|---|---|---|
Mean (SD), US$1000 . | Median (IQR), US$1000 . | |||||
Direct costs | ||||||
Factor use | 867 (380) | 1452 (483) | <.01 | 851 (647-1046) | 1474 (1154-1776) | <.01 |
Other health care | 5 (9) | 4 (6) | .28 | 2 (2-3) | 1 (1–3) | <.01 |
Indirect costs | ||||||
Lost production | 14 (50) | 1 (3) | .08 | 0 (0-0)* | 0 (0-0)* | .82 |
Total costs | 886 (382) | 1457 (484) | <.01 | 852 (659-1094) | 1475 (1155-1787) | <.01 |
IQR, interquartile range; SD, standard deviation.
Ninetieth percentile values were US$30 vs US$2 for Netherlands and Sweden, respectively, in US$1000. Mean costs are influenced by outliers but reflect the total budget at group level, and median costs reflect the cost of the middle person in a skewed distribution.